Publications by authors named "Craig H Selzman"

Heart failure (HF) is a major cause of mortality and morbidity worldwide, yet with limited therapeutic options. Cardiac bridging integrator 1 (cBIN1), a cardiomyocyte transverse-tubule (t-tubule) scaffolding protein which organizes the calcium handling machinery, is transcriptionally reduced in HF and can be recovered for functional rescue in mice. Here we report that in human patients with HF with reduced ejection fraction (HFrEF), left ventricular cBIN1 levels linearly correlate with organ-level ventricular remodeling such as diastolic diameter.

View Article and Find Full Text PDF

Background: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart failure has been controversial.

View Article and Find Full Text PDF

Background: Donation after circulatory death (DCD) heart transplants have increased in the United States with direct procurement with machine perfusion (DPP) and thoracoabdominal normothermic regional perfusion (TA-NRP) techniques. There remains a paucity of data examining DPP and TA-NRP outcomes. The purpose of this study was to investigate the impact of the DCD technique on post-transplant outcomes compared to donation after brain death (DBD) donors.

View Article and Find Full Text PDF

Background: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study's objective was to compare costs between patients treated with and without a Shock Team and determine if the team's implementation is cost-effective compared with standard of care.

Methods: We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiac arrest affects over 600,000 people each year in the U.S., and survival rates have not improved. REBOA, typically used for severe trauma cases, is being explored for use in refractory non-traumatic cardiac arrest to improve blood flow to the heart and brain.
  • The study outlined a training program for emergency medicine physicians to perform REBOA in the emergency department, detailing the training and clinical outcomes from their first eight cases, all of which were successfully catheterized on the first attempt.
  • While REBOA placement showed a 37.5% rate of return of spontaneous circulation (ROSC) among patients, none survived to hospital discharge, indicating the need for further
View Article and Find Full Text PDF
Article Synopsis
  • The study explores how incorporating patient-reported outcomes (PROs) can enhance the prediction of hospitalization and mortality risks in patients with heart failure (HF).
  • The research involved 1165 patients with heart failure with reduced ejection fraction (HFrEF) and 456 with preserved ejection fraction (HFpEF), utilizing advanced statistical methods to analyze risk over time.
  • Findings indicated that models including PROs significantly improved risk prediction, demonstrating their value alongside traditional clinical assessments in managing outpatient heart failure.
View Article and Find Full Text PDF

Background: Cardiogenic shock (CS) can stem from multiple causes and portends poor prognosis. Prior studies have focused on acute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most cases. We studied patients suffering ADHF-CS to identify clinical factors, early in their trajectory, associated with a higher probability of successful outcomes.

View Article and Find Full Text PDF

Background: Cardiogenic shock (CS) mortality remains near 40%. In addition to inadequate cardiac output, patients with severe CS may exhibit vasodilation. We aimed to examine the prevalence and consequences of vasodilation in CS.

View Article and Find Full Text PDF

Background: Type 2 diabetes is prevalent in cardiovascular disease and contributes to excess morbidity and mortality. We sought to investigate the effect of glycemia on functional cardiac improvement, morbidity, and mortality in durable left ventricular assist device (LVAD) recipients.

Methods And Results: Consecutive patients with an LVAD were prospectively evaluated (n=531).

View Article and Find Full Text PDF
Article Synopsis
  • The HeartMate 3 (HM3) is the only fully magnetically levitated left ventricular assist device (LVAD) available for advanced heart failure patients, but its impact on heart function post-implantation hasn't been fully explored.
  • A study comparing HM3 to older LVADs (HeartWare Ventricular Assist Device and HeartMate II) found no significant differences in heart function improvements after implantation.
  • The proportion of patients showing significant reverse heart remodeling was similar across all devices, indicating that HM3 technology may be just as effective as older models in supporting heart recovery.
View Article and Find Full Text PDF

Centrifugal-flow left ventricular assist devices (CF-LVADs) have improved morbidity and mortality for their recipients. Hospital readmissions remain common, negatively impacting quality of life and survival. We sought to identify risk factors associated with hospital readmissions among patients with CF-LVADs.

View Article and Find Full Text PDF

Left ventricular assist devices (LVADs) are excellent therapies for advanced heart failure patients either bridged to transplant or for lifetime use. LVADs also allow for reverse remodeling of the failing heart that is often associated with functional improvement. Indeed, growing enthusiasm exists to better understand this population of patients, whereby the LVAD is used as an adjunct to mediate myocardial recovery.

View Article and Find Full Text PDF

Introduction: Since the 2018 change in the US adult heart allocation policy, more patients are bridged-to-transplant on temporary mechanical circulatory support (tMCS). Previous studies indicate that durable left ventricular assist devices (LVAD) may lead to allosensitization. The goal of this study was to assess whether tMCS implantation is associated with changes in sensitization.

View Article and Find Full Text PDF
Article Synopsis
  • Mechanical unloading with left ventricular assist devices (LVADs) can significantly improve heart function in some advanced heart failure patients, and researchers are studying the related clinical and biological changes.
  • In a study involving 208 patients, a combination of clinical data and RNA sequencing was used to identify predictors of heart recovery after LVAD implantation, focusing on factors like ejection fraction and heart size.
  • The results showed that specific clinical indicators and a biological variable (LRRN4CL) were linked to potential recovery, suggesting that this research could enhance diagnosis and treatment strategies for advanced heart failure.
View Article and Find Full Text PDF

Importance: The existing models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD) support might be limited, partly due to lack of external validation, marginal predictive power, and absence of intraoperative characteristics.

Objective: To derive and validate a risk model to predict RVF after LVAD implantation.

Design, Setting, And Participants: This was a hybrid prospective-retrospective multicenter cohort study conducted from April 2008 to July 2019 of patients with advanced heart failure (HF) requiring continuous-flow LVAD.

View Article and Find Full Text PDF

Background: Venoarterial extracorporeal membrane oxygenation (ECMO) provides full hemodynamic support for patients with cardiogenic shock, but optimal timing of ECMO initiation remains uncertain. We sought to determine whether earlier initiation of ECMO is associated with improved survival in cardiogenic shock.

Methods And Results: We analyzed adult patients with cardiogenic shock who received venoarterial ECMO from the international Extracorporeal Life Support Organization (ELSO) registry from 2009 to 2019, excluding those cannulated following an operation.

View Article and Find Full Text PDF

The use of temporary mechanical circulatory support in cardiogenic shock (CS) is increasing. The Impella (Abiomed) is a percutaneous, microaxial ventricular assist device approved for short-term use in CS that can be implanted peripherally. Direct aortic placement is an alternative commonly performed when the sternum is open, for example, in post-cardiotomy shock or when the peripheral vasculature is of insufficient size or quality for implantation.

View Article and Find Full Text PDF
Article Synopsis
  • Mitochondrial ion channels help cells produce energy and stay alive, but most of them are very specific and open for short times.
  • A new type of channel called LUNA is found all over the body, does not choose which ions to let in, and has a strong current.
  • LUNA is more active when the heart is under stress, which might mean it changes from helping the cell to letting more ions in when the cell is in trouble.
View Article and Find Full Text PDF

Introduction: Recruitment efforts have demonstrated small increases in female and under-represented applicants in recent years; however, the majority of surgical programs remain predominantly Caucasian and male. With increased national emphasis on Diversity, Equity, and Inclusion initiatives and mentoring programs, applicants to surgical specialties have continued to increase. While strategies to improve gender and racial diversity are now openly discussed, it is unclear if we have seen significant improvement.

View Article and Find Full Text PDF

Introduction: Despite advances in antiarrhythmia therapies, ventricular tachycardia (VT) is a leading cause of sudden cardiac death. Investigation into the characteristics and new treatments for this arrhythmia is required to improve outcomes and a reproducible model of VT would be useful in these endeavors. We therefore created a canine model of ischemia-induced VT.

View Article and Find Full Text PDF

Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate around 0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart failure has been controversial.

View Article and Find Full Text PDF

Introduction: Heart transplantation is the treatment of choice for end-stage heart failure. There is a mismatch between the number of donor hearts available and the number of patients awaiting transplantation. Expanding the donor pool is critically important.

View Article and Find Full Text PDF

Organ transplantation with donation after circulatory death can potentially increase the donor pool. Here, we report the rare case of triple-organ (heart/liver/kidney) transplantation from a donor after circulatory death using thoraco-abdominal normothermic regional perfusion. The recipient was a 61-year-old man with end-stage heart failure, liver failure, and kidney failure secondary to arrhythmogenic right ventricular dysplasia.

View Article and Find Full Text PDF

Background: Thoracic aortic disease and bicuspid aortic valve (BAV) likely have a heritable component, but large population-based studies are lacking. This study characterizes familial associations of thoracic aortic disease and BAV, as well as cardiovascular and aortic-specific mortality, among relatives of these individuals in a large-population database.

Methods: In this observational case-control study of the Utah Population Database, we identified probands with a diagnosis of BAV, thoracic aortic aneurysm, or thoracic aortic dissection.

View Article and Find Full Text PDF